Friday, Jan 17, 2003
Front Page |
Southern States |
Other States |
Advts: Classifieds | Employment | Obituary |
Net consolidated sales, after deducting trade discounts, were Rs. 1,058.90 crores ($218 million) and Rs. 3,711.30 crores ($764 million) for Q4 and the year 2002, reflecting a growth of 31 per cent and 39 per cent respectively over the corresponding periods of 2001.
Consolidated profit after tax was Rs.191.70 crores ($39 million) in Q4 and Rs. 608.40 crores ($125 million) in the year ended December 31, 2002 (conversion at Rs. 48.59 a dollar)
In Q4, Ranbaxy Laboratories recorded sales of Rs. 808.80 crores (Rs. 569 crores), registering a growth of 42 per cent. Net Sales at Rs. 776.40 crores grew by 45 per cent. Export sales at Rs. 547.10 crores (Rs. 308.60 crores) registered 77 per cent growth. R&D expenditure (including regulatory expenditure for Q4) was Rs. 47.10 crores (Rs. 17.40 crores). The profit before extraordinary items and tax has spurted to Rs. 220.30 crores from Rs. 60.30 crores) and the net profit after tax to Rs. 212.70 crores (Rs. 50.30 crores).
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |
Copyright © 2003, The
Hindu. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of